NEVO is a Brazilian AI-powered platform that screens suspicious skin lesions from smartphone photos and prioritizes patients by urgency level. It automates triage using a modified Manchester Protocol classification, enabling public health systems and clinics to direct scarce dermatology resources toward higher-risk cases. The platform claims 93% accuracy in field validation and emphasizes medical accountability, with all final diagnoses remaining under physician responsibility.
Funding
Funding not disclosed
Founders
Product
Problem
Skin cancer diagnosis in Brazil is often delayed due to long wait times in the public health system, with patients facing waits of up to three years for dermatological evaluation. When diagnosed late, skin cancer treatment can cost up to 200 times more, straining limited healthcare budgets and leading to preventable deaths.
Solution
NEVO provides an AI-driven triage platform that classifies photos of skin lesions taken with a standard smartphone into four urgency levels based on an adapted Manchester Protocol. The system is designed to be simple, scalable, and accessible, requiring no specialized medical equipment. Photos are captured by health professionals or physicians and automatically prioritized, flagging high-risk cases for urgent specialist review. Clinical responsibility remains with the doctor, who evaluates the case and signs the report, while NEVO supports the workflow rather than autonomously emitting diagnoses.
Target Audience
Primary customers are public health institutions (SUS), primary care networks, and dermatology clinics in Brazil that need to prioritize high-risk skin cancer cases and reduce specialist bottlenecks.
Features
- Smartphone-based image capture with no dependency on specialized dermoscopic devices
- Automatic classification into four urgency tiers (Leve, Não urgente, Pouco grave, Pouco urgente, Grave, Urgente, Emergência, Muito urgente) following the adapted Manchester Protocol
- Native Brazilian dataset of over 1 million validated images, the first of its kind for skin cancer screening in the country
- High-accuracy model validated in field trials: 93% accuracy across 2,058 screenings conducted over 7 months in partnership with SENAR Goiás and the Instituto do Câncer de Pele
- Integration adaptable to each institution's workflow and referral flow, with implementation tailored to team and patient population